Children in the world's poorest countries to get free insulin

Novo NordiskNovo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.

It is estimated that some 38,000 African children aged 0–14 have type 1 diabetes. Sick children are particularly vulnerable in poor countries. A child in sub-Saharan Africa diagnosed with type 1 diabetes has a life expectancy of less than one year. A child with the same condition in the developed world has the possibility to live a full life.

"The premature death of a child caused by lack of insulin is unacceptable, when a life-saving solution is available. We must work together across borders to keep these children from dying; this is why I welcome this new programme being launched by Novo Nordisk today," says Professor Jean Claude Mbanya, president-elect of the International Diabetes Federation (IDF).

The programme will be based on a hub-and-spoke concept (satellite centres around existing hospitals/clinics) aimed at building long-term solutions for improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes.

"As a diabetes care company we have an obligation to use our resources and expertise to help these children. This project will not only provide insulin free of charge to an extremely vulnerable group, it is also designed to build long-term solutions for insulin distribution and sustainable diabetes care for all people with diabetes in the world's poorest countries," says Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S.

To this end, the project’s aim is to collaborate with as many local partners as possible, including governments and diabetes associations, regional chapters of the International Diabetes Federation (IDF) and key opinion leaders. Efforts to improve the healthcare infrastructure of participating countries will also help the programme to survive after the project period ends.

"The World Diabetes Foundation is committed to funding capacity building, awareness creation and development of sustainable infrastructure within existing structures to improve the care for children with diabetes in developing countries. We will work with Novo Nordisk and other relevant stakeholders to achieve this objective," says Anil Kapur, managing director for the World Diabetes Foundation (WDF).

Novo Nordisk announced the 'Changing the Future for Children with Diabetes' programme in connection with the 60th anniversary of the United Nations Universal Declaration of Human Rights.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...